Literature DB >> 34225553

A profile of the binx health io® molecular point-of-care test for chlamydia and gonorrhea in women and men.

Barbara Van Der Pol1, Charlotte A Gaydos2.   

Abstract

Introduction: Point-of-care (POC) tests for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are urgently needed to control the STI epidemic in order to offer patients an immediate diagnoses and accurate treatment before they leave a clinical encounter and thus reduce transmission and sequelae. Nucleic acid amplification tests (NAATs) have increased sensitivity and specificity, but very few POC assays can provide results of such tests within the usual time of the patient visit.Areas covered: This review describes the technology and performance characteristics of the binx health io® [Boston, MA] (binx io) CT/NG assay, a new rapid molecular POC assay. The assay is compared to other available molecular POC tests. We also describe the importance of time to results and assay performance for this POC assay.Expert opinion: The binx io CT/NG assay offers the ability to incorporate the use of POC tests to identify and immediately treat chlamydia and gonococcal infections into the clinical visit, which will provide improved outcomes for patients. Additional implementation studies are needed to optimize the adoption of this new test.

Entities:  

Keywords:  Chlamydia trachomatis; Molecular Diagnostics; Neisseria gonorrhoeae; Point of Care testing; Sexually Transmitted Diseases; binx health

Mesh：

Year:  2021        PMID： 34225553      PMCID： PMC9126586          DOI： 10.1080/14737159.2021.1952074

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN： 1473-7159            Impact factor:   5.670


  41 in total

1.  Meta-analysis of the Cepheid Xpert® CT/NG assay for extragenital detection of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) infections.

Authors:  Claire C Bristow; Sheldon R Morris; Susan J Little; Sanjay R Mehta; Jeffrey D Klausner
Journal:  Sex Health       Date:  2019-08       Impact factor: 2.706

Review 2.  Review: Electrochemical DNA sensing - Principles, commercial systems, and applications.

Authors:  Martin Trotter; Nadine Borst; Roland Thewes; Felix von Stetten
Journal:  Biosens Bioelectron       Date:  2020-02-03       Impact factor: 10.618

3.  Chlamydia trachomatis infection in asymptomatic men.

Authors:  D Scott LaMontagne; David N Fine; Jeanne M Marrazzo
Journal:  Am J Prev Med       Date:  2003-01       Impact factor: 5.043

4.  Point-of-care testing for infectious diseases: diversity, complexity, and barriers in low- and middle-income countries.

Authors:  Nitika Pant Pai; Caroline Vadnais; Claudia Denkinger; Nora Engel; Madhukar Pai
Journal:  PLoS Med       Date:  2012-09-04       Impact factor: 11.069

5.  Detection of Chlamydia trachomatis and Neisseria gonorrhoeae with the cobas CT/NG v2.0 test: performance compared with the BD ProbeTec CT Qx and GC Qx amplified DNA and Aptima AC2 assays.

Authors:  Melinda B Nye; John Osiecki; Michael Lewinski; Oliver Liesenfeld; Stephen Young; Stephanie N Taylor; Rebecca A Lillis; Barbara A Body; Carol Eisenhut; Edward W Hook Iii; Barbara Van Der Pol
Journal:  Sex Transm Infect       Date:  2018-08-20       Impact factor: 3.519

6.  Evaluation of the Performance of the Cobas CT/NG Test for Use on the Cobas 6800/8800 Systems for Detection of Chlamydia trachomatis and Neisseria gonorrhoeae in Male and Female Urogenital Samples.

Authors:  Barbara Van Der Pol; Kenneth Fife; Stephanie N Taylor; Melinda B Nye; Steven E Chavoustie; David L Eisenberg; LaShonda Crane; Gregory Hirsch; Rodney Arcenas; Elizabeth M Marlowe
Journal:  J Clin Microbiol       Date:  2019-03-28       Impact factor: 5.948

Review 7.  Diagnosing sexually transmitted infections in resource-constrained settings: challenges and ways forward.

Authors:  Teodora Ec Wi; Francis J Ndowa; Cecilia Ferreyra; Cassandra Kelly-Cirino; Melanie M Taylor; Igor Toskin; James Kiarie; Nancy Santesso; Magnus Unemo
Journal:  J Int AIDS Soc       Date:  2019-08       Impact factor: 5.396

8.  Clinical Performance of the BD CTGCTV2 Assay for the BD MAX System for Detection of Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis Infections.

Authors:  Barbara Van Der Pol; Edith Torres-Chavolla; Salma Kodsi; Charles K Cooper; Thomas E Davis; Kenneth H Fife; Stephanie N Taylor; Michael H Augenbraun; Charlotte A Gaydos
Journal:  Sex Transm Dis       Date:  2021-02-01       Impact factor: 3.868

9.  Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016.

Authors:  Jane Rowley; Stephen Vander Hoorn; Eline Korenromp; Nicola Low; Magnus Unemo; Laith J Abu-Raddad; R Matthew Chico; Alex Smolak; Lori Newman; Sami Gottlieb; Soe Soe Thwin; Nathalie Broutet; Melanie M Taylor
Journal:  Bull World Health Organ       Date:  2019-06-06       Impact factor: 9.408

10.  Sensitivity, specificity, inclusivity and exclusivity of the updated Aptima Combo 2 assay, which provides detection coverage of the new diagnostic-escape Chlamydia trachomatis variants.

Authors:  Magnus Unemo; Marit Hansen; Ronza Hadad; Mirja Puolakkainen; Henrik Westh; Kaisu Rantakokko-Jalava; Carina Thilesen; Michelle J Cole; Iryna Boiko; Pham T Lan; Daniel Golparian; Shin Ito; Martin Sundqvist
Journal:  BMC Infect Dis       Date:  2020-06-16       Impact factor: 3.090
View more
  2 in total

Review 1.  Facilitators and barriers to point-of-care testing for sexually transmitted infections in low- and middle-income countries: a scoping review.

Authors:  Kevin Martin; Rhys Wenlock; Tom Roper; Ceri Butler; Jaime H Vera
Journal:  BMC Infect Dis       Date:  2022-06-20       Impact factor: 3.667

Review 2.  Bridging the gap between development of point-of-care nucleic acid testing and patient care for sexually transmitted infections.

Authors:  Kuangwen Hsieh; Johan H Melendez; Charlotte A Gaydos; Tza-Huei Wang
Journal:  Lab Chip       Date:  2022-02-01       Impact factor: 7.517
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.